Evidence for a Novel Mechanism Independent of Myocardial Iron in β-Thalassemia Cardiac Pathogenesis

PLoS ONE

Volumn 7, Issue 12, 2012, Pages

  Stoyanova, Ekatherina ^a   Cloutier, Guy ^b   Felfly, Hady ^a   Lemsaddek, Wafaa ^a   Ah Son, Nicolas ^a   Trudel, Marie ^a  

^a CLIN RESEARCH INSTITUTE OF MONTREAL   (Canada)

^b CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

IRON;

ANEMIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BETA THALASSEMIA; CONTROLLED STUDY; DETERIORATION; ERYTHROCYTE COUNT; FEMALE; HEART DISEASE; HEART INDEX; HEART LEFT VENTRICLE CONTRACTILITY; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE FAILURE; HEART LEFT VENTRICLE HYPERTROPHY; HEART MUSCLE FIBROSIS; HEART OUTPUT; HISTOPATHOLOGY; IRON OVERLOAD; IRON STORAGE; MALE; MEAN ARTERIAL PRESSURE; MOLECULAR PATHOLOGY; MOUSE; NONHUMAN; SYSTOLIC DYSFUNCTION; TRANSTHORACIC ECHOCARDIOGRAPHY;

ANIMALS; BETA-THALASSEMIA; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; HEART DISEASES; HEART VENTRICLES; HOMOZYGOTE; HUMANS; IRON; MALE; MICE; MYOCARDIUM; PHENOTYPE;

MURINAE; MUS;

EID: 84871320641     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0052128     Document Type: Article

References (45)

1. Engle MA, Ehlers KH, O'Loughlin JE, Giardina PJ, Hilgartner MW, (1985) Beta thalassemia and heart disease: three decades of gradual progress. Trans Am Clin Climatol Assoc 96: 24-33.
2. Modell B, Khan M, Darlison M, Westwood MA, Ingram D, et al. (2008) Improved survival of thalassaemia major in the UK and relation to T2* cardiovascular magnetic resonance. J Cardiovasc Magn Reson 10: 42.
3. Schrier SL, Angelucci E, (2005) New strategies in the treatment of the thalassemias. Annu Rev Med 56: 157-171.
4. Weatherhall DJ, Clegg JB, editors (2001) The Thalassemia Syndromes. Oxford.
5. Cunningham MJ, Macklin EA, Neufeld EJ, Cohen AR, (2004) Complications of beta-thalassemia major in North America. Blood 104: 34-39.
6. Hahalis G, Alexopoulos D, Kremastinos DT, Zoumbos NC, (2005) Heart failure in beta-thalassemia syndromes: a decade of progress. Am J Med 118: 957-967.
7. Brili SV, Tzonou AI, Castelanos SS, Aggeli CJ, Tentolouris CA, et al. (1997) The effect of iron overload in the hearts of patients with beta-thalassemia. Clin Cardiol 20: 541-546.
8. Aessopos A, Berdoukas V, Tsironi M, (2008) The heart in transfusion dependent homozygous thalassaemia today-prediction, prevention and management. Eur J Haematol 80: 93-106.
9. Aessopos A, Farmakis D, Hatziliami A, Fragodimitri C, Karabatsos F, et al. (2004) Cardiac status in well-treated patients with thalassemia major. Eur J Haematol 73: 359-366.
10. Origa R, Barella S, Argiolas GM, Bina P, Agus A, et al. (2008) No evidence of cardiac iron in 20 never- or minimally-transfused patients with thalassemia intermedia. Haematologica 93: 1095-1096.
11. Aessopos A, Farmakis D, Deftereos S, Tsironi M, Tassiopoulos S, et al. (2005) Thalassemia heart disease: a comparative evaluation of thalassemia major and thalassemia intermedia. Chest 127: 1523-1530.
12. Skow LC, Burkhart BA, Johnson FM, Popp RA, Popp DM, (1983) A mouse model for beta-thalassemia. Cell 34: 1043-1052.
13. Stoyanova E, Trudel M, Felfly H, Garcia D, Cloutier G, (2007) Characterization of circulatory disorders in β-thalassemic mice by noninvasive ultrasound biomicroscopy. Physiol Genomics 29: 84-90.
14. Felfly H, Trudel M, (2010) Successful correction of murine sickle cell disease with reduced stem cell requirements reinforced by fractionated marrow infusions. Br J Haematol 148: 646-658.
15. Felfly H, Trudel M, (2007) Long-term Correction of β-Thalassemia With Minimal Cellular Requirement and Transplantation Modalities. Mol Ther 15: 1701-1709.
16. Beauchemin H, Blouin MJ, Trudel M, (2004) Differential Regulatory and Compensatory Responses in Hematopoiesis/Erythropoiesis in α- and β-Globin Hemizygous Mice. J Biol Chem 279: 19471-19480.
17. Sahn DJ, DeMaria A, Kisslo J, Weyman A, (1978) Recommendations regarding quantitation in M-mode echocardiography: results of a survey of echocardiographic measurements. Circulation 58: 1072-1083.
18. Wandt B, Bojo L, Tolagen K, Wranne B, (1999) Echocardiographic assessment of ejection fraction in left ventricular hypertrophy. Heart 82: 192-198.
19. Pollick C, Hale SL, Kloner RA, (1995) Echocardiographic and cardiac Doppler assessment of mice. J Am Soc Echocardiogr 8: 602-610.
20. Yang XP, Liu YH, Rhaleb NE, Kurihara N, Kim HE, et al. (1999) Echocardiographic assessment of cardiac function in conscious and anesthetized mice. Am J Physiol 277: H1967-1974.
21. Anand IS, (2008) Heart failure and anemia: mechanisms and pathophysiology. Heart Fail Rev 13: 379-386.
22. Roy SB, Bhatia ML, Mathur VS, Virmani S, (1963) Hemodynamic Effects of Chronic Severe Anemia. Circulation 28: 346-356.
23. Naito Y, Tsujino T, Matsumoto M, Sakoda T, Ohyanagi M, et al. (2009) Adaptive response of the heart to long-term anemia induced by iron deficiency. Am J Physiol Heart Circ Physiol 296: H585-593.
24. Bahl VK, Malhotra OP, Kumar D, Agarwal R, Goswami KC, et al. (1992) Noninvasive assessment of systolic and diastolic left ventricular function in patients with chronic severe anemia: a combined M-mode, two-dimensional, and Doppler echocardiographic study. Am Heart J 124: 1516-1523.
25. Olivetti G, Quaini F, Lagrasta C, Ricci R, Tiberti G, et al. (1992) Myocyte cellular hypertrophy and hyperplasia contribute to ventricular wall remodeling in anemia-induced cardiac hypertrophy in rats. Am J Pathol 141: 227-239.
26. Pereira AA, Sarnak MJ (2003) Anemia as a risk factor for cardiovascular disease. Kidney Int Suppl: S32-39.
27. Sun X, Hoage T, Bai P, Ding Y, Chen Z, et al. (2009) Cardiac hypertrophy involves both myocyte hypertrophy and hyperplasia in anemic zebrafish. PLoS ONE 4: e6596.
28. Aessopos A, Deftereos S, Farmakis D, Corovesis C, Tassiopoulos S, et al. (2004) Cardiovascular adaptation to chronic anemia in the elderly: an echocardiographic study. Clin Invest Med 27: 265-273.
29. Bowens C Jr, Spahn DR, Frasco PE, Smith LR, McRae RL, et al. (1993) Hemodilution induces stable changes in global cardiovascular and regional myocardial function. Anesth Analg 76: 1027-1032.
30. Iimoto DS, Covell JW, Harper E, (1988) Increase in cross-linking of type I and type III collagens associated with volume-overload hypertrophy. Circ Res 63: 399-408.
31. Telfer PT, Warburton F, Christou S, Hadjigavriel M, Sitarou M, et al. (2009) Improved survival in thalassemia major patients on switching from desferrioxamine to combined chelation therapy with desferrioxamine and deferiprone. Haematologica 94: 1777-1778.
32. Lombardo T, Tamburino C, Bartoloni G, Morrone ML, Frontini V, et al. (1995) Cardiac iron overload in thalassemic patients: an endomyocardial biopsy study. Ann Hematol 71: 135-141.
33. Tanner MA, Galanello R, Dessi C, Westwood MA, Smith GC, et al. (2006) Myocardial iron loading in patients with thalassemia major on deferoxamine chelation. J Cardiovasc Magn Reson 8: 543-547.
34. Wood JC, Tyszka JM, Carson S, Nelson MD, Coates TD, (2004) Myocardial iron loading in transfusion-dependent thalassemia and sickle cell disease. Blood 103: 1934-1936.
35. Jensen PD, (2004) Evaluation of iron overload. Br J Haematol 124: 697-711.
36. Anderson LJ, Holden S, Davis B, Prescott E, Charrier CC, et al. (2001) Cardiovascular T2-star (T2*) magnetic resonance for the early diagnosis of myocardial iron overload. Eur Heart J 22: 2171-2179.
37. Papakonstantinou O, Alexopoulou E, Economopoulos N, Benekos O, Kattamis A, et al. (2009) Assessment of iron distribution between liver, spleen, pancreas, bone marrow, and myocardium by means of R2 relaxometry with MRI in patients with beta-thalassemia major. J Magn Reson Imaging 29: 853-859.
38. Mavrogeni SI, Markussis V, Kaklamanis L, Tsiapras D, Paraskevaidis I, et al. (2005) A comparison of magnetic resonance imaging and cardiac biopsy in the evaluation of heart iron overload in patients with beta-thalassemia major. Eur J Haematol 75: 241-247.
39. Pennell DJ, Berdoukas V, Karagiorga M, Ladis V, Piga A, et al. (2006) Randomized controlled trial of deferiprone or deferoxamine in beta-thalassemia major patients with asymptomatic myocardial siderosis. Blood 107: 3738-3744.
40. Kawabata H, Germain RS, Ikezoe T, Tong X, Green EM, et al. (2001) Regulation of expression of murine transferrin receptor 2. Blood 98: 1949-1954.
41. Qian ZM, Chang YZ, Leung G, Du JR, Zhu L, et al. (2007) Expression of ferroportin1, hephaestin and ceruloplasmin in rat heart. Biochim Biophys Acta 1772: 527-532.
42. Kato GJ, Gladwin MT, Steinberg MH, (2007) Deconstructing sickle cell disease: reappraisal of the role of hemolysis in the development of clinical subphenotypes. Blood Rev 21: 37-47.
43. Morris CR (2008) Mechanisms of vasculopathy in sickle cell disease and thalassemia. Hematology Am Soc Hematol Educ Program: 177-185.
44. Reiter CD, Wang X, Tanus-Santos JE, Hogg N, Cannon RO III, et al. (2002) Cell-free hemoglobin limits nitric oxide bioavailability in sickle-cell disease. Nat Med 8: 1383-1389.
45. Stoyanova E, Trudel M, Felfly H, Lemsaddek W, Garcia D, et al. (2012) Vascular Endothelial Dysfunction in beta-Thalassemia Occurs Despite Increased eNOS Expression and Preserved Vascular Smooth Muscle Cell Reactivity to NO. PLoS ONE. 7: e38089.